Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest drug discovery Stories

2014-03-05 08:28:45

Publication Further Validates Lpath's Approach to Targeting Bioactive Lipids for Drug Discovery SAN DIEGO, March 5, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has brought scientists one step closer to finding a potential treatment for traumatic brain injury (TBI) with a recent publication showing that Lpathomab(TM), a therapeutic antibody, reverses much of the damage caused by trauma to the nervous system. As...

2014-03-04 08:32:04

SAN DIEGO, March 4, 2014 /PRNewswire/ -- Absorption Systems, a global leader in preclinical contract testing of drugs, biologics, and medical devices, is pleased to announce that Dr. Glenwood Gum, Associate Director, Preclinical Operations, will present a talk at the 6(th) Ocular Diseases & Drug Discovery Conference on March 20(th) in San Diego. The title of his presentation is "Developing Predictive Preclinical Models for Novel Anterior Segment Drug Delivery." The conference,...

2014-03-01 23:01:36

MarketResearchReports.Biz announces addition of new report “Global Data Storage Device Manufacturers Industry” to its database. Visit: http://www.marketresearchreports.biz/analysis-details/data-storage-device-manufacturers-global-industry-report. (PRWEB) March 01, 2014 Data Storage Device Manufacturers (Global) Analysis provides a detailed overview of the Data Storage Device Manufacturers (Global) market and delivers a comprehensive individual analysis on the top 490 companies,...

2014-02-28 08:25:18

SAN DIEGO and PRINCETON, N.J., Feb. 28, 2014 /PRNewswire/ -- Abide Therapeutics today announced it has entered into a strategic collaboration with Celgene Corporation to discover and develop new drugs in inflammation and immunology. Abide has pioneered innovative technologies to selectively target serine hydrolases, one of the largest enzyme families involved in regulating human physiology. (Logo: http://photos.prnewswire.com/prnh/20130502/LA06084LOGO) Under the terms of the...

2014-02-27 23:27:06

Selexis CSO Demonstrates How the Selexis SURE CHO-Mplus™ Libraries Can Dramatically Improve Biologic Protein Expression in Mammalian Cell Lines Geneva, Switzerland (PRWEB) February 27, 2014 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today it will host a free webinar to educate scientists and researchers about the SURE CHO-Mplus™ Libraries to...

2014-02-27 23:24:43

The global high content screening (HCS) market is segmented on the basis of products, applications, end users, and geography. http://www.marketsandmarkets.com/Market-Reports/high-content-screening-market-42710391.html (PRWEB) February 27, 2014 The “High Content Screening Market by Instruments (Cell Imaging and Analysis System) by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global...

2014-02-27 16:28:16

ThermoDox Demonstrates Impressive Response Rate in Refractory Patients LAWRENCEVILLE, N.J., Feb. 27, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial will enroll 20 patients at 5 clinical sites in the United States and is evaluating ThermoDox in combination with mild hyperthermia. Based on data available to date, a...

2014-02-27 16:27:40

SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires' lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the U.S. and European Union for the treatment of pulmonary arterial hypertension. "The addition of AIR001 provides us with not only an exciting phase 2 asset in the area of pulmonary disease,...

2014-02-25 23:26:17

Selexis to Meet with Biopharmaceutical Companies Interested in Protein Drug Discovery, Cell Line Development and Lead Identification for Therapeutic Drug Development and Manufacturing Geneva, Switzerland (PRWEB) February 25, 2014 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that representatives from the Company will be participating in the...

2014-02-24 23:23:34

High Throughput Screening (HTS) is a drug-discovery process that leverages automation to quickly assay the biochemical activity of numerous drug-like compound - http://www.marketsandmarkets.com/Market-Reports/high-throughput-screening-market-134981950.html. (PRWEB) February 24, 2014 According to the new market research report the “High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (UHTS), Label Free, Bioinformatics), by Applications (Target...